STAAR Surgical Company (STAA): Price and Financial Metrics
STAA Stock Summary
- With a price/earnings ratio of 713.79, Staar Surgical Co P/E ratio is greater than that of about 98.91% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for STAA is currently 201.45, higher than 97.56% of US stocks with positive operating cash flow.
- STAA's price/sales ratio is 25.82; that's higher than the P/S ratio of 92.08% of US stocks.
- Stocks that are quantitatively similar to STAA, based on their financial statements, market capitalization, and price volatility, are RP, DLB, NTGR, VRNT, and MITK.
- Visit STAA's SEC page to see the company's official filings. To visit the company's web site, go to www.staar.com.
STAA Stock Price Chart Interactive Chart >
STAA Price/Volume Stats
|Current price||$90.64||52-week high||$128.23|
|Prev. close||$95.10||52-week low||$23.20|
|Day high||$95.19||Avg. volume||906,831|
|50-day MA||$99.23||Dividend yield||N/A|
|200-day MA||$69.16||Market Cap||4.22B|
STAAR Surgical Company (STAA) Company Bio
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company was founded in 1982 and is based in Monrovia, California.
STAA Latest News Stream
|Loading, please wait...|
STAA Latest Social Stream
View Full STAA Social Stream
Latest STAA News From Around the Web
Below are the latest news stories about Staar Surgical Co that investors may wish to consider to help them evaluate STAA as an investment opportunity.
Update since my last note Since my bullish note on Staar Surgical (STAA) in November last year the company's shares have risen by 26%, from $82, to $104 at the time of writing. Until the recent market pullback - which has hit the Nasdaq especially hard - Staar's share price...
STAAR Surgical Company (STAA) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Brian Moore - VP, Investor, Media Relations and Corporate Development Caren Mason - President and CEO Patrick Williams - Chief Financial Officer Conference Call Participants Chris Cooley - Stephens, Inc. Anthony Petrone -...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended January 1, 2021. Fourth Quarter 2020 Overview Net Sales of $46.0 Million Up 18% from the Prior Year Quarter ICL Sales of $39.8 Million Up 20% from the Prior Year Quarter ICL Units Up 13% from the Prior Year Quarter Gross Margin at
Shares of Staar Surgical (NASDAQ:STAA) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 16.67% over the past year to $0.14, which beat the estimate of $0.02. Revenue of $45,998,000 higher by 18.30% year over year, which beat the estimate of $43,850,000. Looking Ahead Earnings guidance hasn't been issued by the company for now. Staar Surgical hasn't issued any revenue guidance for the time being. Conference Call Details Date: Feb 24, 2021 View more earnings on STAA Time: 04:30 PM ET Webcast URL: https://event.on24.com/wcc/r/2947844/77947360158D9121D30E2109E9A9C9CD Price Action Company's 52-week high was at $128.23 52-week low: $23.20 Price action over last quarter: Up 57.29% Company Description Staar Surgical Co is ...
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / STAAR Surgical Co. (NASDAQ:STAA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 4:30 PM Eastern Time.
STAA Price Returns
Continue Researching STAAWant to do more research on Staar Surgical Co's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!